Unicycive Therapeutics (UNCY) Accounts Payables (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Accounts Payables came in at $1.0 million in Q1 2026, down 27.42% YoY from $1.4 million in Q1 2025, and up 164.75% on a QoQ basis from $383000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) Accounts Payables (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Accounts Payables data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Accounts Payables fell 27.42% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 27.42% YoY) and the FY2025 annual result came in at $383000.0, down 63.8% from the prior year.
- Accounts Payables advanced to $1.0 million in Q1 2026, from $383000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.3 million in Q3 2022 to a low of $383000.0 in Q4 2025.
- A 5-year average of $1.0 million and a median of $846000.0 in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables surged 4577.55% — and 2025, when it tumbled 63.8%.
- Tracing UNCY's Accounts Payables over 5 years: stood at $846000.0 in 2022, then jumped by 136.41% to $2.0 million in 2023, then sank by 47.1% to $1.1 million in 2024, then plunged by 63.8% to $383000.0 in 2025, then jumped by 164.75% to $1.0 million in 2026.
- The last three Accounts Payables figures came in at $1.0 million (Q1 2026), $383000.0 (Q4 2025), and $717000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.23 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 383,000.00 |
| Sep 30, 2025 | 717,000.00 |
| Jun 30, 2025 | 775,000.00 |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 519,000.00 |
| Jun 30, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | 990,000.00 |
| Jun 30, 2023 | 503,000.00 |
| Mar 31, 2023 | 790,000.00 |
| Dec 31, 2022 | 846,000.00 |
| Sep 30, 2022 | 2.29 Mn |
| Jun 30, 2022 | 747,000.00 |
| Mar 31, 2022 | 589,000.00 |
| Dec 31, 2021 | 742,000.00 |
| Sep 30, 2021 | 49,000.00 |